British Journal of Haematology

Article	Citations
e‐Posters	145
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	122
Don't forget cord blood in non‐remission acute myeloid leukaemia!	121
Issue Information	88
Issue Information	85
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	81
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	79
	76
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	75
Issue Information	75
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	72
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	67
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	65
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	62
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	61
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	56
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	55
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	54
The role of genetics in refractory immune thrombocytopenia	53
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	53
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	52
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	50
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	49
Immune thrombocytopenia (ITP) in pregnancy	49
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	48

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	48
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	47
Immunophenotypic clustering in paediatric acute myeloid leukaemia	46
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	46
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	46
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	44
Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials	42
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	39
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	39
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	38
Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma	38
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	38
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	38
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.	37
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle	36
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	36
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	36
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	35
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	34
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	34
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	34
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells	33
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	30
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	30
The oldest case of lymphoma? Insights from a XIII century fresco	30
Indirect presentation of mismatched human leukocyte antigen‐B associates with outcomes of cord blood transplantation	29
How to dose and monitor argatroban for treatment of HIT	29
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	29
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	29
Screening for monoclonal gammopathy of undetermined significance is contraindicated	28
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	28
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	28
Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia	28
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews	28
	28
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	28
Would you like to take some more ruxolitinib after your fedratinib?	27
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	27
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	27
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	27
Prolonged platelet hyperactivity after COVID‐19 infection	26
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	26
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	25
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	25
Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia	25
Issue Information	25
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	25
Are HPA‐5b antibodies a significant cause of FNAIT and associated bleeding or merely an incidental finding?	24
	24
Issue Information	24

A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies	24
Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring	23
Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers	23
Another side of IgA neoplastic plasma cells	23
Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload	23
Issue Information	23
Correction to “Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib”LiM, LiuL, DingB, SongX, XiaA, HanY, et al. Refractory/relapse thrombocytope	23
	23
Obituary Dr Christine Costello: MBChB, DRCOG, FRCP, FRCPath 29 August 1945–31 December 2021	23
	23
Erratum to: The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia	23
Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia	22
A synonymous variant is unmasked in thalassaemia	22
Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis	22
Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment	21
Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup	21
A single dose of eculizumab terminated life‐threatening haemolysis in idiopathic IgM‐mediated warm autoimmune haemolytic anaemia: A case report	21
A defined serum‐free culture system for human long‐term haematopoietic stem cells	21
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma	20
Immature platelets in COVID‐19 infection	20
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia	20
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia	20
Management of cardiovascular complications of bruton tyrosine kinase inhibitors	20
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia	20
Bridging the implementation gap in medication adherence. If you build it, will they come?	20
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features	20
Iron parameters in pregnant women with beta‐thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supple	20
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia	19
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia	19
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report	19
Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real‐world clinical practices	19
Clinical decision support to reduce unnecessary diagnostic testing for heparin‐induced thrombocytopenia	19
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients	19
Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state	19
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma—Response	19
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T‐ALL	19
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study	19
Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma	19
Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma	19
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia	18
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post‐transplant clinical outcome in patients with aggressive ATL	18
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy	18
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome	18
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease	18
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study	18
Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents	18
Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease	18
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis	18
Factor VII deficiency: A cause of (or risk factor for) bleeding?	18
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	18
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant	18
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model	18
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics	18
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	18
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia	18
Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone marrow	18
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease	18
Association of human leucocyte antigen loci with vaccine‐induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4‐derived peptides and MHC‐	18
Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis	18
Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation	18
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis	18
	17
Issue Information	17
	17
Issue Information	17
Multiple myeloma with acicular crystalline inclusion bodies	17
Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies	17
Issue Information	17
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells	17
	17
Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)	17
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment	17
Issue Information	17
Inflammatory profile of lower risk myelodysplastic syndromes	16
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis	16
The impact of B‐cell‐directed therapy on SARS‐CoV‐2 vaccine efficacy in chronic lymphocytic leukaemia	16
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder	16
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect	16
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study	16
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study	16

External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registr	16
Erratum	16
Issue Information	16
Biochemical screening of glucose‐6‐phosphate dehydrogenase deficiency in borderline cases: Complementary inputs of standardization enzymes and comparison with genetic status	16
How to discover the exceptional venetoclax responders in AML/MDS?	16
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study	16
Up‐regulation of miR‐130a is related to leg ulcers in sickle cell anaemia	16
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies	16
The usefulness of indium‐111 platelet scintigraphy beyond predicting efficacy of splenectomy	16
	16
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa	16
A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures, rib anomalies and extremely short telomere lengths with high serum IgE	16
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas	16
Spurious thrombocytosis, red cell count and mean cell volume in a patient with thermal burns	16
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis	15
High on‐treatment platelet reactivity—an OPTIMAl solution, or a better solution?	15
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?	15
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan	15
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report	15
Prognostic impact of FLT3‐ITD mutation on NPM1+ acute myeloid leukaemia patients and related molecular mechanisms	15
Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?	15
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3‐PBX1 positive acute lymphoblastic leukaemia	15
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response	15
Survival prediction optimization of acute myeloid leukaemia based on T‐cell function‐related genes and plasma proteins	15
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation fr	15
Hedgehog blockade in steroid‐refractory sclerotic chronic graft‐versus‐host disease	15
Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia	15
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis	15
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients	15
Impact of pre‐eclampsia on renal outcome in sickle cell disease patients	15
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study	15
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation	15
Effect of peptide‐binding motif on survival of HLA‐haploidentical transplantation with post‐transplant cyclophosphamide	15
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study	14
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	14
Idecabtagene vicleucel: questions regarding the appropriate role and cost	14
The distribution and accumulation of the shortest telomeres in telomere biology disorders	14
PF4 promotes CXCR3+ Tfh1 cell differentiation through STAT1 in mouse immune thrombocytopenia	14
Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study	14
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia	14
Dimethyl fumarate ameliorates graft‐versus‐host disease by inhibiting T‐cell metabolism and immune responses through a reactive oxygen species‐dependent mechanism	14
Chronic refractory immune thrombocytopenia in adolescents and young adults	14
Cryoglobulin crystals deposited in a peripheral blood film and phagocytosed by neutrophils	14
Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real‐world’ report from the GRNDaD registry	14
Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and pa	14
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	14
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights	14
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia	14
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial	14
Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission	14
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target	14
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study	14
Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia	14
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia	14
Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes	14
The Russian invasion of Ukraine: Implications for haematologists	13
Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India	13
Forecasting optimal treatments in relapsed/refractory mature T‐ and NK‐cell lymphomas: A global PETAL Consortium study	13
Different phenotypes with different endings—Telomere biology disorders and cancer predisposition with long telomeres	13
Issue Information	13
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma	13
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis	13
Erratum	13
Gene therapy with B‐cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma	13
Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymph	13
Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation	13
Oral iptacopan for paroxysmal nocturnal haemoglobinuria—First real‐world experience	13
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency	13
Issue Information	13
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia	13
Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?	13
Expression of Concern: Effect of insulin‐like growth factor 1 on PHA‐stimulated cord blood mononuclear cell telomerase activity	13
Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study	13
Effectiveness of in vivo T‐cell‐depleted regimen containing porcine anti‐lymphocyte globulin or rabbit anti‐thymocyte globulin in preventing acute graft‐versus‐host disease after haploidentical haemat	13
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia	13
	13
Development of a novel test of splenic function for use in a clinical diagnostic laboratory	13
Proteomic analysis of neutrophils from patients with COVID‐19	13
	13
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	13
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm	13
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia	12
The Menin story in acute myeloid leukaemia—The road to success	12
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia	12
Quad‐class exposed/refractory myeloma is associated with short survival	12
Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow	12
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma	12
Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: A population‐based study	12
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications	12
Everyone is entitled to his or her own opinion but not to their own facts*	12
The potential impact of monkeypox infection and vaccination on blood donor deferrals and the blood supply	12
Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists	12
Prevalence of anti‐platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines—A systematic review and meta‐analysis	12
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment	12
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia	12